MA53270A - Diazabicyclooctanones en tant qu'inhibiteurs de bêta-lactamases à sérine - Google Patents

Diazabicyclooctanones en tant qu'inhibiteurs de bêta-lactamases à sérine

Info

Publication number
MA53270A
MA53270A MA053270A MA53270A MA53270A MA 53270 A MA53270 A MA 53270A MA 053270 A MA053270 A MA 053270A MA 53270 A MA53270 A MA 53270A MA 53270 A MA53270 A MA 53270A
Authority
MA
Morocco
Prior art keywords
diazabicyclooctanones
serin
beta
lactamase inhibitors
lactamase
Prior art date
Application number
MA053270A
Other languages
English (en)
Other versions
MA53270B1 (fr
Inventor
David Thomas Davies
Simon Leiris
Original Assignee
Antabio Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antabio Sas filed Critical Antabio Sas
Priority claimed from PCT/EP2019/071370 external-priority patent/WO2020030761A1/fr
Publication of MA53270A publication Critical patent/MA53270A/fr
Publication of MA53270B1 publication Critical patent/MA53270B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA53270A 2018-12-18 2019-08-08 Diazabicyclooctanones comme inhibiteurs de sérine beta-lactamases MA53270B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18213635.8A EP3670512A1 (fr) 2018-12-18 2018-12-18 Diazabicyclooctanones comme inhibiteurs de sérine beta-lactamases
PCT/EP2019/071370 WO2020030761A1 (fr) 2018-08-09 2019-08-08 Diazabicyclooctanones en tant qu'inhibiteurs de bêta-lactamases à sérine

Publications (2)

Publication Number Publication Date
MA53270A true MA53270A (fr) 2022-04-06
MA53270B1 MA53270B1 (fr) 2023-11-30

Family

ID=64745939

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53270A MA53270B1 (fr) 2018-12-18 2019-08-08 Diazabicyclooctanones comme inhibiteurs de sérine beta-lactamases

Country Status (4)

Country Link
EP (1) EP3670512A1 (fr)
EA (1) EA202190444A1 (fr)
MA (1) MA53270B1 (fr)
PT (1) PT3833665T (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2533826T3 (es) * 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
CN103649088B (zh) * 2011-08-30 2016-05-11 沃克哈特有限公司 1, 6- 二氮杂双环[3, 2, 1]辛- 7- 酮衍生物及其在治疗细菌感染中的用途
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
GB2533136A (en) 2014-12-11 2016-06-15 Antabio Sas Compounds
CN107501265B (zh) * 2017-10-09 2019-05-28 台州职业技术学院 一种7-氧代-二氮杂二环[3,2,1]辛烷衍生化合物及其制备方法和应用

Also Published As

Publication number Publication date
EP3670512A1 (fr) 2020-06-24
PT3833665T (pt) 2023-10-19
MA53270B1 (fr) 2023-11-30
EA202190444A1 (ru) 2021-06-18

Similar Documents

Publication Publication Date Title
MA54547A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA54546A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA44725A (fr) Formulations d'un inhibiteur de lsd1
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
MA52413A (fr) Inhibiteurs de cd73
MA51232A (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
DK3687994T3 (da) Gadolinium-bærende pcta-baserede kontrastmidler
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
MA48765A (fr) Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub
MA52063A (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA51616A (fr) Inhibiteurs d'adn-pk
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA52942A (fr) Composés inhibiteurs d'oga
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA46242A (fr) Composés inhibiteurs de bêta-lactamase
MA52939A (fr) Composés inhibiteurs d'oga
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA47420A (fr) Composés inhibiteurs d'oga